^
Association details:
| Biomarker: | KEAP1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P83.01 - Updated Survival and Biomarker Analysis of Camrelizumab and Apatinib in Previously Treated pts of Advanced Non-Squamous NSCLC
Published date:
01/12/2021
Excerpt:
Patients of non-squamous NSCLC who received apatinib 250 mg orally once daily in combination with camrelizumab 200 mg intravenously on day 1 every 2 weeks...patients with STK11/KEAP1 mutation had a numerically higher ORR (42.9% vs 28.1%, P =0.327), longer PFS (median 9.4 vs 5.3, P = 0. 592) and statistically significantly longer OS (median NR vs NR, P = 0. 047) than those of wild type…Combined camrelizumab and apatinib had promising antitumor activity...especially in these with STK11 or KEAP1 mutation...
Trial ID:
